Precipio inc.

FORM 8-K. CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 1, 2021 PRECIPIO, INC.The undersigned, the duly qualified and appointed Chief Financial Officer of Precipio, Inc., a Delaware corporation (the “Company”), does hereby certify in such capacity and on behalf of the Company, pursuant to Section 7(m) of the Sales Agreement, dated April [ ], 2023 (the “Sales Agreement”), between the Company and A.G.P./Alliance ...Sep 21, 2023 · NEW HAVEN, Conn., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. ( NASDAQ: PRPO) today announced that it has implemented a 1-for-20 reverse stock split of ... Precipio, Inc. (PRPO) Stock Price, Quote, News & Analysis PRPO Precipio, Inc. Stock Price & Overview 5.5K followers $6.83 -0.17 ( -2.48%) 12:19 PM …

Precipio, Inc. (NASDAQ:PRPO) Q3 2021 Earnings Conference Call November 15, 2021 5:00 PM ETCompany Participants. Ilan Danieli - CEO. Conference Call Participants. Operator. Welcome to the Precipio ...Seasoned, experienced industry executive with a track record of managing 9-figure revenue sales organizations. NEW HAVEN, CT – (Globenewswire) – (June 13 th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that Keith Meadors has joined Precipio as its Senior Vice President of its Products Division, to manage and drive company growth and market ...After the upgrade, the solo analyst covering Precipio is now predicting revenues of US$15m in 2023. If met, this would reflect a substantial 39% improvement in sales compared to the last 12 months ...

Follow. NEW HAVEN, Conn., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced it has signed an exclusive global distribution agreement ...Precipio Launched its Proprietary HemeScreen AML (Acute Myeloid Leukemia) Molecular Panel. September 22 nd, 2020; Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), launched its ...

Q1-2020 Net Revenues increase 77% over Q4-2019 to $1.2M. (GlobeNewswire) May-12-20 05:00PM. Precipio Announces Q1-2020 Corporate Update Call For Shareholders. (GlobeNewswire) Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP ... Precipio Corporate Deck. Who is Precipio? We are creating clinically impactful, cost-effective cancer diagnostic technologies to eliminate laboratory diagnostic errors. Discover how we excel as a blood cancer laboratory, dedicated to specialized diagnostic services for physicians and patients. Learn more at Precipio.Precipio, Inc. (PRPO) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 7.00 -0.22 (-3.05%) At close: 03:20PM EST 6.74 +0.01 (+0.15%) After hours: 04:09PM EST Summary Company...The complaint alleged that Carl Iberger was at the time the CFO of Precipio and learned this confidential information through his position as CFO. According to the complaint, on July 30, 2020, the company announced the agreement and Precipio's stock price rose substantially. Allegedly, the day before the announcement, Timothy Iberger …

Precipio Services. Precipio Services provides consulting services and software enhancements for Microsoft Dynamics GP. We specialize in Microsoft Dynamics GP …

Tracfone Wireless Inc has been a leading player in the telecommunications industry, offering innovative solutions and cutting-edge technology to its customers. With a focus on providing reliable and affordable wireless services, Tracfone ha...

Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and ...Precipio’s IV-Cell ® culturing media is a critical reagent intended to be used by cytogenetics laboratories to simplify, speed up and provide greater accuracy of their hematologic (blood cancer ...Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses.Precipio Announces Q3-2023 Shareholder Update Call. Globe Newswire • 16 days ago. Track Precipio Inc (PRPO) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors.Precipio, Inc. NEW HAVEN, Conn., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces its Pathology Division has in August exceeded the ...About Precipio. Precipio Inc. is a healthcare company focused on cancer diagnostics. The Company’s mission is to address the pervasive problem of cancer misdiagnosis by developing products to ...August 13, 2023 at 10:16 AM · 3 min read. It's not a stretch to say that Precipio, Inc.'s ( NASDAQ:PRPO) price-to-sales (or "P/S") ratio of 0.9x right now seems quite "middle-of-the-road" for ...

Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and ... Jun 8, 2023 · NEW HAVEN, Conn., June 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced it has entered into securities purchase agreements with ... NEW HAVEN, Conn., June 08, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has launched the HemeScreen ® Anemia Panel as part of its suite ...On January 13, 2020 Precipio, Inc. (the “Company”) issued a press release.As noted in the press release, management will host an update conference call where management will provide a strategic business update and will respond to questions submitted in advance via email initiatives on Monday 20, 2020, at 5:00pm Eastern Time.Corporate Office and Clinical Lab. 4 Science Park, 3rd Floor New Haven, CT 06511 203-787-7888. Research and Development. 8813 F Street Omaha, NE 68127 203-787-7888 ext. 570partners, Precipio has developed several cutting-edge technologies to provide unparalleled diagnostic accuracy. Precipio has partnered with top academic institutions to deliver highly specialized pathology expertise. In addition to the clinical suspicion, Omnia’s proprietary algorithm considers clinical history and CBCThe average Web Designer I salary in the United States is $67,135 as of October 25, 2023, but the range typically falls between $59,939 and $74,962. Salary ranges can vary widely depending on many important factors, including education, certifications, additional skills, the number of years you have spent in your profession.

On August 22, 2017, Precipio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Aegis Capital Corp. (“Aegis”), relating to the issuance and sale of 6,000 units consisting of one share of the Company’s Series B Preferred Stock, par value $0.01 per share (“Series B Preferred Stock”), which is convertible into 400 …The average Web Designer I salary in the United States is $67,135 as of October 25, 2023, but the range typically falls between $59,939 and $74,962. Salary ranges can vary widely depending on many important factors, including education, certifications, additional skills, the number of years you have spent in your profession.

Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses.Precipio, Inc. (NASDAQ:PRPO) Q2 2023 Earnings Call Transcript August 17, 2023 Precipio, Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.1. Operator: Welcome to the Precipio Second Quarter 2023 Shareholder Update Conference Call.Track Precipio Inc (PRPO) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsOn November 11, 2020, Precipio, Inc (the "Company") announced that management will host a Q3-2020 Corporate Update Call for Shareholders on Thursday, November 19th, 2020 at 5:00 PM EST. A copy of the letter is attached hereto as Exhibit 99.1 and incorporated herein by reference.NEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced another 4-year agreement with a new customer to bring HemeScreen™ technology into their laboratory. Based on the customer’s expected patient volume, with the addition of this customer, revenues in Q1-2023 are now ...4747690069000001043961--12-312021Q3false1757691622708292P7DP10DP1D3000300030003000P5Y0001043961prpo:LincolnParkMember2018-09-072018-09-070001043961prpo ...Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses.Exhibit 99.1 . Precipio Takes Final Step towards Regaining Nasdaq Compliance. Company announces 1-for-15 reverse stock split . NEW HAVEN, CT - (April 26, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has implemented a 1-for-15 reverse stock split of outstanding shares of the company's …

When it comes to staying informed and up-to-date with the latest news, there are countless options available. One popular choice for many people is Apple News, a news aggregator developed by Apple Inc.

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services.

Precipio, Inc. | 2,193 followers on LinkedIn. Precipio’s vision is to battle the problem of cancer misdiagnosis by creating innovative diagnostic products. | Since its inception in 2011 ... Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and ...C/O PRECIPIO, INC. 4 SCIENCE PARK (Street) NEW HAVEN: CT: 06511 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol Precipio, Inc. [ PRPO] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X: Director: 10% Owner: X: Officer (give title below)NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Precipio, Inc. (NASDAQ: PRPO), please note that the 5th paragraph should read ...Mar 28, 2023 · Conference Call to be held on Monday, April 3rd, 2023 at 5:00 PM ETNEW HAVEN, Conn., March 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be ... On August 1, 2017, Precipio, Inc. (the “Company”) filed a preliminary prospectus supplement to the base prospectus included in the Company’s shelf registration statement on Form S-3 (No. 333-201907), filed with the Securities and Exchange Commission (the “SEC”) on February 6, 2015 and declared effective by the SEC on February 13, 2015. …Follow. NEW HAVEN, Conn., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced it has signed an exclusive global distribution agreement ...Seasoned, experienced industry executive with a track record of managing 9-figure revenue sales organizations. NEW HAVEN, CT – (Globenewswire) – (June 13 th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that Keith Meadors has joined Precipio as its Senior Vice President of its Products Division, to manage and drive company growth and market ...Item 1.01 Entry into Material Definitive Agreement . At The Market Offering Agreement . On April 2, 2021, Precipio, Inc (the “Company’) entered into a sales agreement with A.G.P./Alliance Global Partners (“A.G.P.”), pursuant to which the Company may offer and sell its common stock, par value $0.01 per share (the “Common Stock”) (the “Shares”), …Dec 6, 2022 · December 06, 2022 10:00 ET | Source: Precipio, Inc. NEW HAVEN, Conn., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced a 4-year ... FORM 8-K. CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 1, 2021 PRECIPIO, INC.C/O PRECIPIO, INC. 4 SCIENCE PARK (Street) NEW HAVEN: CT: 06511 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol Precipio, Inc. [ PRPO] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director: 10% Owner: X: Officer (give title below)

Precipio’s R&D team estimates a development time of under 4 months for this assay, and a cost of less than $50,000, an unprecedented speed and development cost in this industry.On August 1, 2017, Precipio, Inc. (the “Company”) filed a preliminary prospectus supplement to the base prospectus included in the Company’s shelf registration statement on Form S-3 (No. 333-201907), filed with the Securities and Exchange Commission (the “SEC”) on February 6, 2015 and declared effective by the SEC on February 13, 2015. …Conference Call to be held on November 20th, 2023 at 5:00 PM ESTNEW HAVEN, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be ...Instagram:https://instagram. financial advisors utahprop firm traderev revolutionouter outdoor furniture NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Precipio, Inc. (NASDAQ: PRPO), please note that the 5th paragraph should read ...Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing ... stocks below dollar10cryptocurrency broker in usa Corporate Office and Clinical Lab. 4 Science Park, 3rd Floor New Haven, CT 06511 203-787-7888. Research and Development. 8813 F Street Omaha, NE 68127 203-787-7888 ext. 570 how to trade stocks on fidelity Precipio expects the project to be completed by the end of Q1 2020. On December 17th, Precipio announced the receipt of their first commercial order for IV-Cell from Northwell Health. Precipio estimates generating considerable six-figures in annual revenues to the company as the first midsize customer to adopt IV-Cell.51.31%. Get the latest Precipio Inc (PRPO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment …Precipio, Inc. announced that Keith Meadors has joined Precipio as its Senior Vice President of its Products Division, to manage and drive company growth and market share. Keith brings over 30 years of executive experience in various healthcare organizations, including his recent position as Vice President of Marketing at Fresenius Kabi.